The clinical relevance of PI3K pathway deregulation should be evaluated in the context of breast cancer molecular subtypes as these subtypes differ in survival outcome, treatment response, and frequency of PIK3CA mutations and PTEN loss [6],[15]–[18]. Here, PIK3CA is linked to breast cancer.